Helix BioPharma Partners with ProMab on CAR-T Therapies

Article

The collaboration between the two companies aims to finish all necessary work needed to file for a first-in-human study by early 2019.

Helix BioPharma, an immuno-oncology company, has signed a collaboration agreement with ProMab Biotechnologies to develop novel antibody and chimeric antigen receptor T-cell (CAR-T) therapy for particular hematological malignancies, such as multiple myeloma, the company announced in a March 21, 2018 press release.

Helix had previously announced the signing of a binding letter of intent with ProMab to develop CAR-T for various hematological malignancies and solid tumors.  The company has now signed its first scientific collaboration to co-develop a cell-based therapy for multiple myeloma (MM).

The MM co-development program will aim to complete all necessary work and intends to file for a first-in-human study by early 2019.  Under the agreement, Helix will retain commercial rights for this CAR-T product in Canada and Europe and is currently in the process of reviewing the expansion criteria required for its European operations in Poland to facilitate commercialization.

Source: Helix BioPharma

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Recent Videos
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
DC skyline at night with view of the White House and the Washington Monument | Image Credit: © Jessica - stock.adobe.com
Related Content
© 2025 MJH Life Sciences

All rights reserved.